Patanjali Foods Limited (PFL) has announced its financial results for the quarter ended June 30, 2025, posting a revenue of ₹8,899.70 crore, a 24% increase compared to ₹7,177.17 crore in the same quarter last year. While rural demand remained stable during the quarter, urban demand was subdued, and competition from regional and direct-to-consumer (D2C) brands intensified.
Financial Performance
In Q1 FY26, PFL recorded a total EBITDA of ₹334.17 crore, with ₹86.83 crore contributed by the Food and Other FMCG segment and ₹119.50 crore from the Home and Personal Care (HPC) segment. Net profit (PAT) stood at ₹180.39 crore, translating into a PAT margin of 2.02%. The company generated export revenue of ₹39.34 crore from shipments to 27 countries. Its palm oil plantation area reached 92,133 hectares, with 43.44% in the high-yielding phase.
Market Challenges
During the quarter, inflation dropped to 2.1% in June—the lowest in three years. However, demand for non-essential and premium FMCG products was weak, impacted by government welfare schemes and duty-free imports of yellow peas. Globally, excess palm oil supply and a halving of import duty on crude oils in India made palm oil prices more competitive compared to sunflower and soybean oil.
To stimulate urban demand, the company launched smaller SKUs and value packs, which showed early signs of recovery. Its Samriddhi Urban Loyalty Program helped boost repeat orders and brand availability.
Food and Other FMCG Segment
This segment reported revenue of ₹1,660.67 crore, accounting for 18.46% of total revenue, with an EBITDA of ₹86.83 crore and a margin of 5.23%. The biscuits category recorded ₹451.40 crore in revenue, with the Doodh brand contributing ₹304 crore, up 15% year-on-year. Ghee sales reached ₹256.98 crore, a 23% YoY increase, while nutraceuticals posted ₹17.31 crore in sales, up 37.60% YoY. New launches such as Cholesterol Care Liquid and Ortho Care Liquid received a positive response. Textured soy products achieved revenue of ₹139.69 crore, marking a 36% quarter-on-quarter growth.
Home and Personal Care Segment
The HPC segment earned ₹639.02 crore in revenue, driven by dental care (₹332.18 crore), skin care (₹157.21 crore), and home care (₹91.61 crore). The segment’s EBITDA was ₹119.50 crore, contributing 35.98% to total EBITDA. Key brands like Dant Kanti, Kesh Kanti, and Saundarya performed well, with the company focusing on premium Dant Kanti variants, including Advanced, Sensitive, Aloe Vera, Red, and Medicated Gel. HPC products were exported to nine countries, with Dant Kanti in high demand.
Edible Oils Segment
The edible oils segment recorded revenue of ₹6,685.86 crore, up 25.34% YoY, with branded oils contributing 72% of the total. Mustard and sunflower oil sales saw strong quarter-on-quarter growth. The segment’s EBITDA was ₹119.10 crore, with a margin of 1.78%, affected by changes in customs duties and inventory valuation.
Wind Turbine Power Generation
The wind turbine power generation segment earned ₹11.87 crore in revenue, benefiting from increased electricity output. This segment remains a stable income contributor within the company’s diversified portfolio.
Expansion and Outlook
PFL expanded its presence in central India with new direct outlets and strengthened its rural reach through a super stockist network, rural distributor programs, and rural health centres. With low inflation, improved liquidity from the Reserve Bank of India, and a good monsoon, demand is expected to rise in the second half of FY26.
Exports during the quarter included products such as ghee, biscuits, juices, and textured soy protein. The company’s focus on premium offerings in both HPC and food portfolios is aimed at driving long-term growth and profitability.
About Patanjali Foods
Founded in 1986, Patanjali Foods Limited is one of India’s leading FMCG companies, operating across edible oils, food and FMCG, home and personal care, and wind power generation. Its major brands include Patanjali, Ruchi Gold, Nutrela, and Dant Kanti, catering to diverse consumer segments through an extensive product portfolio and brand-building initiatives.
Also Read: Cardiogrit Gold Proven Effective Against Doxorubicin-Induced Cardiotoxicity: Patanjali Study
